Congress is going after another drugmaker for pricing a decades-old drug at $89,000
View all Offers
OnePlus Nord 2 5G (Blue Haze, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
OnePlus Nord 2 5G (Gray Sierra, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
- 18% OFF
Redmi 9 (Carbon Black, 4GB RAM, 64GB Storage) | Extra INR 200 Amazon Pay Cashback | 2.3GHz Mediatek Helio G35 Octa core Processor₹ 8999₹ 10999Buy On
- 19% OFF
Redmi Note 10 (Aqua Green, 4GB RAM, 64GB Storage) -Amoled Dot Display | 48MP Sony Sensor IMX582 | Snapdragon 678 Processor₹ 12999₹ 15999Buy On
- 20% OFF
Redmi 9A (Nature Green, 2GB RAM, 32GB Storage) | 2GHz Octa-core Helio G25 Processor | 5000 mAh Battery₹ 6799₹ 8499Buy On
Marathon has said that the intended net price for the drug after rebates and discounts will be $54,000 a year. That's still much more than the $1,200 a year price of the medicine in other countries, where the drug has been around for a few decades."We believe Marathon is abusing our nation's "orphan drug" program, which grants companies seven years of market exclusivity to encourage research into new treatments for rare diseases - not to provide companies like Marathon with lucrative market exclusivity rights for drugs that have been available for decades," Sanders and Cummings wrote. The two also encouraged the company to decrease the list price before the drug goes on the market officially in March.
Marathon did not immediately return a request for comment on the letter.This isn't the first time the duo have asked about drug prices. The two have been calling out everything from expensive cancer drugs to price hikes on old medications. It's also not the first time the two have written to Marathon. The closely-held company once owned Nitropress and Isuprel, two heart drugs that have been criticized for their dramatic price increases. The move is reminiscent of a plan former pharma CEO Martin Shkreli had with a treatment for another rare disease.
While CEO of KaloBios, Shkreli had told investors that he planned to price a drug called benznidazole that's used to treat the neglected parasitic infection Chagas disease somewhere in the $60,000-to-$100,000 per-treatment range. The decades-old drug hasn't been approved in the US, but it's used around the world and provided in specific instances to the US for free.
Marathon will also get a priority review voucher, which are granted to companies which develop treatments for rare diseases as a way to add incentives on drugs that otherwise wouldn't have much commercial value. Thomson Reuters
The voucher can then be used by the company to speed up its review time for another drug, or it can be sold to another company that wants to fast-track its drug by a few months. These vouchers have been sold for up to $350 million. Sanders and Cummings had questions about that as well, as part of their overarching question to figure out how much Marathon stands to make from Emflaza's approval.
Marathon now has until February 27 to respond to the congressmen's questions.
- Canon’s new patent hints at a telephoto lens attachment for smartphones under development
- Kerala-based ESAF Small Finance Bank looks to raise ₹998 crore through IPO
- Meet BeachBot, a beach rover that uses AI to remove cigarette butts from beaches
- Amazon Prime Day 2021: Best deals and offers on health and household products
- Odisha’s temple town Puri becomes first Indian city with drinkable tap water available throughout the day